New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences
May 08, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications SEATTLE and LUND, Sweden, May 08, 2018 (GLOBE NEWSWIRE)...
Aptevo Therapeutics Announces IND Submission for APVO436
May 01, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing On Track to Commence Phase 1...
Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
April 16, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor...
Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update
March 13, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million Forms Strategic Bispecific Antibody Partnership with Alligator Bioscience Demonstrating Versatility of the ADAPTIR™...
Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY
March 12, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America SEATTLE, March 12, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on...
Aptevo Therapeutics to Present at the 30th Annual ROTH Conference
February 27, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...
Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
January 08, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it...
Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples
December 11, 2017 09:02 ET
|
Aptevo Therapeutics Inc.
New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens SEATTLE, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a...
Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma
November 28, 2017 07:02 ET
|
Aptevo Therapeutics Inc.
Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates SEATTLE, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on...
Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 14, 2017 16:02 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...